Omeprazole A2845: Practical Research Workflow

Omeprazole (SKU A2845) is supplied for experimental workflows investigating proton pump inhibition, gastric acid secretion, and antiulcer mechanisms. The compound is chemically identified as 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide, with a molecular formula of C17H19N3O3S and a molecular weight of 345.42. The APExBIO product dossier reports approximately 98% purity and describes the material as a potent H+,K+-ATPase inhibitor.

Because no directly matched paper evidence is being used for this article, the numerical specifications below are limited to the product dossier. Experimental recommendations are presented as workflow guidance and should be verified against the selected cell system, enzyme preparation, detection method, and institutional procedures.

What This Product Solves

Many gastric acid secretion research workflows require a defined chemical perturbation to test whether an assay responds to proton pump inhibition. Omeprazole A2845 can serve as the test article in biochemical, cellular, or preclinical studies that measure acid formation, secretory responses, or downstream lesion-related endpoints. It is therefore relevant to gastric acid secretion research, an antiulcer activity study, and a peptic ulcer disease model when the experimental design has been independently validated.

The dossier lists an IC50 of 5.8 μM for H+,K+-ATPase inhibition and an IC50 of 0.16 μM for histamine-induced acid formation. These values can help researchers plan an initial concentration range, but they should not be treated as universal potency constants. IC50 values depend on substrate or stimulant concentration, enzyme abundance, incubation conditions, cell state, endpoint timing, and the mathematical model used for curve fitting.

For a protocol-focused companion, see Omeprazole (A2845) Protocols for Gastric Acid Secretion Research; it is most relevant when building a gastric acid secretion assay around this compound. For additional handling context, see Omeprazole (A2845): Technical Guidance for Gastric Acid Research, which complements this article with related practical guidance.

Protocol Parameters

Protocol Parameters

• Assay: H+,K+-ATPase inhibition; Value: IC50 5.8 μM; Applicability: biochemical proton pump assays and concentration-response planning; Rationale: provides a dossier-reported reference point for the stated target assay; Evidence basis: product dossier.
• Assay: Histamine-induced acid formation; Value: IC50 0.16 μM; Applicability: cellular or tissue-based acid secretion experiments using histamine stimulation; Rationale: supports selection of an initial test range for a secretory endpoint, followed by assay-specific optimization; Evidence basis: product dossier.
• Compound preparation: DMSO stock solution; Value: reported solubility ≥17.27 mg/mL in DMSO; Applicability: preparation of concentrated research stocks before dilution into the assay system; Rationale: the dossier identifies Omeprazole as insoluble in water and ethanol, making DMSO the specified solvent option; Evidence basis: product dossier.
• Identity and calculation: molecular mass; Value: 345.42 g/mol; Applicability: conversion between weighed mass, molar concentration, and assay dosing; Rationale: use the stated molecular weight when preparing accurately documented stocks; Evidence basis: product dossier.
• Storage: solid material; Value: -20°C; Applicability: long-term storage before solution preparation; Rationale: the dossier identifies frozen solid storage as the preferred stability condition and does not recommend long-term storage of solutions; Evidence basis: product dossier.

Workflow Setup and QC Checklist

Before preparation

• Confirm the product name, SKU A2845, lot information, stated purity, molecular formula, and molecular weight against the accompanying documentation.
• Inspect the vial for labeling integrity, physical damage, or visible abnormalities before opening. Record receipt condition, including the use of blue ice for small-molecule shipping where applicable.
• Define the assay endpoint before selecting concentrations. For gastric acid secretion research, specify whether the readout is proton pump activity, acid formation, a stimulated secretory response, or a downstream cellular signal.

Stock and working-solution handling

• Use the solid to prepare a documented DMSO stock. Calculate the required mass from the molecular weight of 345.42 g/mol, then record solvent volume, preparation date, operator, and intended concentration.
• Do not use water or ethanol as the primary solvent because the dossier reports insolubility in both. Dilute the DMSO stock into the assay medium gradually while mixing, and inspect the final working solution for cloudiness or precipitate.
• Prepare working solutions as close to the experiment as practical. Long-term storage of solution form is not recommended, so any short-term holding condition should be validated within the laboratory and documented.
• Include a vehicle-matched control at the same final DMSO exposure as treated wells or reaction mixtures. Keep solvent exposure consistent across all experimental groups.

Assay QC

• Use untreated and vehicle controls to distinguish compound-associated effects from handling or solvent effects. Include a reference control when the assay has an established internal standard.
• For concentration-response experiments, begin with a range that brackets the relevant dossier values, then adjust after confirming signal window, baseline stability, and curve quality in the specific system.
• Assess compound exposure alongside assay performance indicators such as cell or tissue integrity, background signal, and positive-control response. A reduced signal is not interpretable if the preparation is broadly compromised.
• Document plate position or reaction order, incubation timing, temperature, stimulant concentration, detection settings, and dilution steps. These variables can materially affect apparent IC50 values.

Common Failure Modes and Fixes

Precipitation after dilution

Precipitation commonly results from transferring a DMSO stock too rapidly into an aqueous medium, exceeding practical solubility, or using an insufficient mixing step. Prepare the stock at a concentration compatible with the assay, add it gradually, mix immediately, and inspect the working solution. If precipitation remains, redesign the dilution scheme rather than assuming the nominal concentration represents dissolved compound.

Vehicle-related assay distortion

Unequal DMSO exposure can alter cell performance or assay background and create an apparent treatment effect. Match the vehicle across every condition, including controls and reference treatments. If the assay is unusually solvent-sensitive, establish vehicle tolerance before interpreting Omeprazole response data.

Unstable or poorly documented solutions

Keeping solution stocks for extended periods can introduce uncertainty because long-term solution storage is not recommended in the dossier. Use the solid for storage, prepare solutions close to use, and record preparation and discard dates. Avoid repeated handling cycles and protect the material from unnecessary exposure to conditions outside the validated workflow.

Overinterpretation of potency values

The 5.8 μM and 0.16 μM IC50 values refer to different assay contexts. Applying one value directly to a different cell type, tissue preparation, or endpoint can lead to incorrect dosing assumptions. Report the measured concentration-response relationship from the current experiment and describe the dossier values only as planning references.

Confounding cytotoxicity or tissue injury

A change in acid-related signal may reflect loss of viable cells or damaged tissue rather than selective modulation of the intended endpoint. Pair the primary readout with an appropriate integrity or viability assessment and review the morphology or quality metrics of the preparation. This is particularly important in a peptic ulcer disease model or other preclinical system with multiple injury-related endpoints.

Scope and Limitations

Omeprazole A2845 is intended strictly for scientific research use. It is not a diagnostic reagent, medical product, or treatment for gastric acid-related disorders or peptic ulcer disease. The dossier supports research use in gastric acid secretion mechanisms, antiulcer drug development, and proton pump inhibition, but it does not establish clinical efficacy, therapeutic dosing, or safety in humans.

The stated purity is approximately 98%, which supports routine research use but does not by itself establish sterility, endotoxin status, compatibility with every biological system, or suitability for regulated testing. Researchers should obtain lot-specific documentation when those attributes matter. The chemical name, molecular weight, solvent behavior, storage condition, and reported IC50 values should be treated as product-specific information rather than universal properties of every assay format.

In the absence of directly matched paper evidence, this guide does not assign Omeprazole a particular cell-line response, animal outcome, pharmacokinetic profile, or comparative advantage over other inhibitors. Any extension into a gastric acid-related disorders model should be supported by pilot testing, appropriate controls, and an endpoint-specific validation plan.

Conclusion

Omeprazole A2845 offers a practical research reagent for controlled studies of H+,K+-ATPase inhibition and gastric acid formation. Reliable use depends on preparing the compound in DMSO, avoiding water or ethanol as primary solvents, maintaining matched vehicle controls, storing the solid at -20°C, and treating dossier IC50 values as assay-specific planning references. With documented preparation, precipitation checks, and independent endpoint validation, the material can be incorporated into gastric acid secretion research and antiulcer activity studies without extending the available evidence beyond its defined research scope.